Endometriosis.

TTX334Dx and TTX334e

Endometriosis is a chronic, debilitating and painful disease that affects more than 10 percent of women during their reproductive years and can make it challenging to get pregnant. It occurs when tissue that is supposed to line the uterus is found in other places, usually throughout the pelvis.

Endometriosis is a chronic, debilitating and painful disease that affects more than 10 percent of
women during their reproductive years and can make it challenging to get pregnant. It occurs when
tissue that is supposed to line the uterus is found in other places, usually throughout the pelvis.

The Challenge of Endometriosis

Endometriosis is one of the most prevalent yet under-recognized diseases in women’s health. Affecting at least an estimated 1 in 10 women, it causes chronic pelvic pain, infertility, and reduced quality of life—yet patients routinely wait 7 to 10 years for a diagnosis and can be subjected to numerous surgical procedures, which exacerbates the formation of adhesion and related complications. Despite its scale, meaningful innovation has been limited.

1. Late and Invasive Diagnosis

The biggest challenge in endometriosis is identifying it early and accurately. Symptoms are often normalized or dismissed, and no reliable non-invasive diagnostic test exists. Today, confirmation still requires a surgical procedure (laparoscopy), creating barriers to timely diagnosis and effective management.

2. Symptom Management, Not Cure

Existing therapies—hormonal suppression or surgery—offer temporary relief rather than a lasting solution. Recurrence rates remain high, with up to 50% of women experiencing return of symptoms within two years. Many treatments also compromise fertility or cause intolerable side effects, leaving patients with few sustainable options.

3. Limited Understanding of Disease Biology

Endometriosis is not just a hormonal disorder—it is a chronic inflammatory and fibrotic disease involving complex interactions between the immune system, local tissue environment, and molecular signaling. Yet, research and investment have lagged behind its clinical burden, slowing the development of true disease-modifying therapies.

Our mission is to change this trajectory. Temple Therapeutics is advancing biology-driven solutions designed to redefine how endometriosis is diagnosed and treated—moving from symptom control to mechanism-based intervention.

Temple Therapeutics is redefining the diagnosis and treatment of endometriosis through a multi-pronged, biology-driven approach.

Our clinically validated biobank has enabled the discovery of key blood-based biomarkers, providing new insights into disease mechanisms. Building on this, our Multi-Laser Imaging with AI-assisted Digital Pathology (MLI-AI) platform enhances diagnostic accuracy without the need for surgery.

Together, these platforms form a powerful engine for drug discovery and validation, accelerating the development of non-hormonal, disease-modifying therapeutics that target the root causes of endometriosis rather than just managing symptoms. Temple Therapeutics is advancing precision medicine for women—bringing science closer to meaningful, lasting relief.

We believe women deserve better: earlier detection, targeted therapies, and lasting relief grounded in science and innovation.

  • Exceptionally painful menstrual cramps
  • Pain during or after sex
  • Persistent pain in the lower back and pelvis
  • GI problems, especially during menstrual periods
  • Infertility

Common Symptoms Include

  • Exceptionally painful menstrual cramps
  • Persistent pain in the lower back and pelvis
  • Pain during or after sex
  • GI problems, especially during menstrual periods
  • Infertility

For those with endometriosis, pain often worsens during menstrual periods because endometrial tissue outside the uterus can grow and bleed in sync with a menstrual period. This causes pain because the swelling and blood can’t easily exit the body as menstrual blood can.

Anyone with a uterus can develop endometriosis, but women in their 30s and 40s are particularly impacted. Women who have never had children and those with a family member who has endometriosis are more likely to develop this health problem.

Scientists don’t know what triggers endometriosis. Some possible causes include blockages that prevent menstrual blood from leaving the body, genetics, problems with the immune system that prevent it from inhibiting the growth of endometrial tissue in places where it doesn’t belong, and hormonal imbalances.

Changing the paradigm.

Temple Therapeutics is seeking to change the ways in which endometriosis is both detected and treated.

The current procedure for diagnosis involves laparoscopic surgery using a tiny camera inserted through a small incision, which can be inaccurate and lead to complications. Temple is pioneering an entirely new diagnostic method: the first non-invasive alternative to surgical diagnosis.

This approach will allow for safer, easier, and more accurate confirmation of disease, reducing the financial, physical, and emotional burden on patients and their communities. We are also seeking to improve the available therapies by developing a drug to treat endometriosis.

To bolster our endometriosis work, we are creating a global platform for dialogue among endometriosis patients, their communities, healthcare providers, and scientific experts, building an evidence-based culture of education and support for those suffering from this disease.

10%

Endometriosis affects an estimated 2 to 10 percent of American women of childbearing age.

TTX334Dx for early detection.

Our researchers are developing a panel of biomarkers, TTX334Dx, that has shown an ability in early trials to detect endometriosis with a high level of sensitivity and specificity. These biomarkers, or molecules in the blood, allow earlier detection, identifying disease before it progresses to a more complex stage.

This approach decreases the risk of misdiagnosis and its accompanying complications, while also helping manage the disease by assessing the efficacy of other potential therapies. Temple anticipates launching this diagnostic test in 2023.

TTX334e for early treatment.

We are also developing a drug, TTX334e, intended to treat endometriosis. The drug is currently in preclinical stages. Unlike existing treatments, which include painkillers, surgeries, and hormonal drugs, TTX334e acts by killing fibrotic cells, attacking the root cause of the disease rather than attempting to just mitigate symptoms. We anticipate launching a Phase 1 trial of the drug in 2023.